Antimicrobial activity of non-steroidal anti-inflammatory drugs on biofilm: Current evidence and potential for drug repurposing
RC Paes Leme, RB da Silva - Frontiers in microbiology, 2021 - frontiersin.org
It has been demonstrated that some non-steroidal anti-inflammatory drugs (NSAIDs), like
acetylsalicylic acid, diclofenac, and ibuprofen, have anti-biofilm activity in concentrations …
acetylsalicylic acid, diclofenac, and ibuprofen, have anti-biofilm activity in concentrations …
Potential repurposed drug candidates for tuberculosis treatment: progress and update of drugs identified in over a decade
The devastating impact of Tuberculosis (TB) has been a menace to mankind for decades.
The World Health Organization (WHO) End TB Strategy aims to reduce TB mortality up to …
The World Health Organization (WHO) End TB Strategy aims to reduce TB mortality up to …
Drug re‐engineering and repurposing: A significant and rapid approach to tuberculosis drug discovery
The prevalence of tuberculosis (TB) remains the leading cause of death from a single
infectious agent, ranking it above all other contagious diseases. The problem to tackle this …
infectious agent, ranking it above all other contagious diseases. The problem to tackle this …
[HTML][HTML] Harnessing Host-Pathogen Interactions for Innovative Drug Discovery and Host-Directed Therapeutics to tackle tuberculosis.
S Saini, A Gangwar, R Sharma - Microbiological research, 2023 - Elsevier
Tuberculosis (TB) is a highly contagious bacterial infection caused by Mycobacterium
tuberculosis (Mtb), which has been ranked as the second leading cause of death worldwide …
tuberculosis (Mtb), which has been ranked as the second leading cause of death worldwide …
The prospect of repurposing immunomodulatory drugs for adjunctive chemotherapy against tuberculosis: A critical review
C Lee, S Bhakta - Antibiotics, 2021 - mdpi.com
Tuberculosis (TB) remains a global health emergency, with an estimated 2 billion people
infected across the world, and 1.4 million people dying to this disease every year. Many …
infected across the world, and 1.4 million people dying to this disease every year. Many …
Synthesis and Characterization of New N-acyl Hydrazone Derivatives of Carprofen as Potential Tuberculostatic Agents
N-acyl hydrazone (NAH) is recognized as a promising framework in drug design due to its
versatility, straightforward synthesis, and attractive range of biological activities, including …
versatility, straightforward synthesis, and attractive range of biological activities, including …
Three-dimensional low shear culture of Mycobacterium bovis BCG induces biofilm formation and antimicrobial drug tolerance
D Cantillon, J Wroblewska, I Cooper… - npj Biofilms and …, 2021 - nature.com
Mycobacteria naturally grow as corded biofilms in liquid media without detergent. Such
detergent-free biofilm phenotypes may reflect the growth pattern of bacilli in tuberculous …
detergent-free biofilm phenotypes may reflect the growth pattern of bacilli in tuberculous …
Repurposing anti-inflammatory drugs for fighting planktonic and biofilm growth. New carbazole derivatives based on the NSAID carprofen: synthesis, in silico and in …
Introduction One of the promising leads for the rapid discovery of alternative antimicrobial
agents is to repurpose other drugs, such as nonsteroidal anti-inflammatory agents (NSAIDs) …
agents is to repurpose other drugs, such as nonsteroidal anti-inflammatory agents (NSAIDs) …
Drug repurposing for tuberculosis
NC Cardoso, CB Oosthuizen, N Peton… - … -Molecular Aspects and …, 2021 - books.google.com
Tuberculosis (TB), caused by Mycobacterium tuberculosis, is a major global health concern
given the increase in multiple forms of drug-resistant TB. This underscores the importance of …
given the increase in multiple forms of drug-resistant TB. This underscores the importance of …
[HTML][HTML] Immunobiology of tubercle bacilli and prospects of immunomodulatory drugs to tackle tuberculosis (TB) and other non-tubercular mycobacterial infections
C Daniel, S Bhakta - Immunobiology, 2022 - Elsevier
The COVID-19 pandemic has set back progress made on antimicrobial resistance (AMR).
Without urgent re-focus, we risk slowing down drug discovery and providing treatment for …
Without urgent re-focus, we risk slowing down drug discovery and providing treatment for …